Real-world effectiveness and safety of lisocabtagene maraleucel for relapsed/refractory large B cell lymphoma in Japan
{{output}}
Background: Lisocabtagene maraleucel (liso-cel), an anti-CD19 CAR T cell therapy, has demonstrated efficacy in relapsed/refractory (R/R) large B cell lymphoma (LBCL). However, real-world data from commercial settings outside the ... ...
